Levetiracetam Bristol Labs (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which plays a crucial role in the regulation of neurotransmitter release. This binding modulates synaptic transmission, decreasing abnormal neuronal firing and thereby lowering the likelihood of seizure generation.

The appropriate dose of levetiracetam is individualized and determined by the prescribing clinician based on the patient’s age, weight, renal function, seizure type, and response to therapy. Dosage regimens may vary, and adjustments are made according to clinical judgment.

Safety data for levetiracetam in pregnancy and lactation are limited. The drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details and any necessary import documentation.

Compared with many traditional antiepileptics, levetiracetam has a relatively simple pharmacokinetic profile, low protein binding and minimal hepatic metabolism, resulting in fewer drug‑drug interactions. It is often chosen for its broad spectrum of activity across seizure types and its ease of dosing, though individual response varies.

Store the tablets at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or extreme temperatures.

Levetiracetam Bristol Labs is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, and the dosing schedule (once, twice or multiple times daily) is set by the prescriber based on the individual treatment plan.

Serious risks include severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, as well as neuropsychiatric events like depression, aggression, or suicidal thoughts. Patients should be monitored closely for any signs of rash, mood changes, or unusual behavior, and medical attention should be sought promptly if they occur.

Levetiracetam should be avoided in individuals with known hypersensitivity to the drug or any of its components. Patients with severe renal impairment require careful dose adjustment, and those with uncontrolled psychiatric conditions should be evaluated thoroughly before initiation.